トファシチニブは強直性脊椎炎における椎体と後外側靭帯の炎症を減少: フェーズ2試験結果
Rheumatol Ther. 2023;10(4):1001–1020 doi 10.1007/s40744-023-00564-y
Tofacitinib treatment is associated with a significant improvement in CANDEN MRI scores of spinal inflammation in axSpA patients. This study by Østergaard, et al. also validates the CANDEN MRI scoring system as an approach for measuring axSpA-associated inflammatory lesions.
The phase 2 multicentre, randomized, double-blind, placebo-controlled, dose-ranging trial had three treatment groups over the course of 12 Weeks: Tofacitinib 10 mg BID, tofacitinib 5 mg BID, and placebo. Both tofacitinib doses showed significant improvement in CANDEN scores, while showing an increased number of fat lesions observed using MRI.
Keywords:
